13.93
+1.90%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Telix Pharmaceuticals
Its shares trade on ASX under the ticker TLX.AX. It has been listed since 15 November 2017. In the fiscal year to 31 December 2025, it reported revenue of $803.8m and a net loss of $7.1m. At that date it held total assets of $1.16bn and shareholders' equity of $415.4m.
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The firm's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer). The Company, through its subsidiary TheraPharm GmbH, is engaged in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells, as well as in diagnostics of inflammatory diseases and bone marrow metastases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Nov 2017
- Employees
- 60
- Website
- telixpharma.com ↗
Leadership
Pay as last reported
- Ms. Tiffany OlsonNon-Executive Independent Chairman of the BoardA$203,568
- Dr. Christian BehrenbruchGroup Chief Executive Officer, Managing Director, Executive Director, since 2017A$1.4m
- Mr. Darren SmithGroup Chief Financial OfficerA$1.2m
- Mr. Raphaeel OrtizChief Executive Officer - Telix International
- Mr. Kevin RichardsonChief Executive Officer - Telix Precision Medicine
- Dr. Darren PattiGroup Chief Operating OfficerA$930,735
- Dr. Paul SchafferChief Technology Officer
- Ms. Lena Moran-AdamsGroup General Counsel
- Dr. David CadeGroup Chief Medical Officer, since 2024A$1.1m
- Mr. James StonecypherGroup Chief Development Officer
- Mr. Richard ValeixGroup Chief Commercial OfficerA$1.0m
- Ms. Genevieve RyanCompany Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 34
- Social
- 93
- Governance
- 69
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Telix Pharmaceuticals Ltd has a strong portfolio of innovative and advanced radiopharmaceutical products.
- The company has established strategic partnerships with leading healthcare organizations, which enhances its market presence.
- Telix Pharmaceuticals Ltd has a highly skilled workforce with deep expertise in radiopharmaceutical development and commercialization.
Weaknesses
- The company is heavily dependent on the success of its research and development efforts, which may lead to unpredictable outcomes.
- Telix Pharmaceuticals Ltd faces certain regulatory and compliance challenges in different markets, potentially affecting its growth prospects.
- Limited financial resources may restrict the company's ability to expand and invest in new projects.
Opportunities
- The global radiopharmaceutical market is expected to witness significant growth, providing Telix Pharmaceuticals Ltd with opportunities to expand its market share.
- Advancements in technology and increasing adoption of targeted molecular imaging offer Telix Pharmaceuticals Ltd chances to develop innovative radiopharmaceutical products.
- Growing awareness of personalized medicine and the potential benefits of radiopharmaceuticals present opportunities for Telix Pharmaceuticals Ltd to capitalize on.
Threats
- Competition from established pharmaceutical companies and emerging startups pose threats to Telix Pharmaceuticals Ltd's market position.
- Stringent regulations and reimbursement policies in the healthcare industry may impact the pricing and availability of radiopharmaceutical products, affecting the company's profitability.
- The ongoing COVID-19 pandemic has disrupted healthcare systems worldwide, which could cause delays in clinical trials or market launches of Telix Pharmaceuticals Ltd's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.